Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the...
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the...
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick...
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its...
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of...
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –...
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0...
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...
ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an...
The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study has enrolled the final patient Topline results expected in early July...
San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development SAN JOSE, CA--(February...
Another Finnish municipality, Lapinlahden kunta, has chosen Aino's SaaS solution. The agreement covers a total of approximately 320 employees. Implementation is...
PRESS RELEASE - REGULATED INFORMATION 24 February 2023, 07:00 CET Biocartis Creates New Share Option Plan and Cancels Outstanding Pool...
Press release – No. 1 / 2023 Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –...
MARKHAM, Ontario, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced...
CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales.MELBOURNE, Australia, Feb....